Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation

Trial Profile

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Islet cell replacement therapy (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Sernova Corp
  • Most Recent Events

    • 20 Dec 2018 According to a Sernova media release, company is expecting to report preliminary safety data in the first half of 2019 and preliminary efficacy data in the second half of 2019.
    • 20 Dec 2018 According to a Sernova media release, company expects completion of enrollment of the first patient cohort to be January 2019 and full enrollment to be completed by mid- 2019.
    • 20 Dec 2018 According to a Sernova media release, first patient has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top